IDDF2024-ABS-0267 Continued treatment of early nonresponders or partial virologic responders with bu...
IDDF2024-ABS-0267 Continued treatment of early nonresponders or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis delta through week 96 leads to improvement in virologic and biochemical responses
About this item
Full title
Author / Creator
Yu, Jacques , Lampertico, Pietro , Wedemeyer, Heiner , Brunetto, Maurizia , Bogomolov, Pavel , Stepanova, Tatyana , Ciesek, Sandra , Berger, Annemarie , Manuilov, Dmitry , An, Qi , Lau, Audrey , Da, Ben , Flaherty, John , Mercier, Renee-Claude , Zeuzem, Stefan , Cornberg, Markus , Buti, Maria and Aleman, Soo
Publisher
London: BMJ Publishing Group Ltd and British Society of Gastroenterology
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd and British Society of Gastroenterology
Subjects
More information
Scope and Contents
Contents
BackgroundBulevirtide (BLV) is a first-in-class entry inhibitor for chronic hepatitis D (CHD) which was conditionally approved in the EU. Results from the Week 48 primary endpoint analysis for MYR301, a phase 3 randomized study, showed monotherapy with BLV at 2 or 10 mg/d given subcutaneously was superior to no active anti-HDV treatment e. Here, we...
Alternative Titles
Full title
IDDF2024-ABS-0267 Continued treatment of early nonresponders or partial virologic responders with bulevirtide monotherapy in patients with chronic hepatitis delta through week 96 leads to improvement in virologic and biochemical responses
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3100973875
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3100973875
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gutjnl-2024-IDDF.193
